Hemorrhagic events during the 60-day study period according to initial anticoagulation strategy
| Hemorrhage characteristics . | Full-dose (n = 75) . | Modified-dose (n = 33) . | None (n = 13) . |
|---|---|---|---|
| Total hemorrhage, n (%) | 18 (24) | 5 (15) | 0 |
| Severity of hemorrhage, n (%) | |||
| Fatal hemorrhage | 1 (1) | 0 | 0 |
| Major hemorrhage | 8 (11) | 2 (6) | 0 |
| Clinically relevant nonmajor hemorrhage | 9 (12) | 2 (6) | 0 |
| Minor hemorrhage | 0 | 1 (3) | 0 |
| Type of hemorrhage | |||
| Intracranial hemorrhage | 2 (3) | 1 (3) | 0 |
| Ocular | 0 | 1 (3) | 0 |
| Upper gastrointestinal bleed | 1 (1) | 0 | 0 |
| Lower gastrointestinal bleed | 7 (9) | 1 (3) | 0 |
| Retroperitoneal | 1 (1) | 0 | 0 |
| Hematuria | 4 (5) | 0 | 0 |
| Mucocutaneous | 4 (5) | 2 (6) | 0 |
| Intramuscular | 1 (1) | 0 | 0 |
| Anticoagulant dose at time of hemorrhage | |||
| Full-dose | 15 (20) | 4 (12) | — |
| Modified-dose | 3 (4) | 1 (3) | — |
| None | 1 (1) | 0 | — |
| Anticoagulant at time of hemorrhage | |||
| LMWH | 10 (13) | 2 (6) | — |
| Unfractionated heparin | 4 (5) | 1 (3) | — |
| Direct oral anticoagulant | 4 (5) | 2 (6) | — |
| Median days with platelet count <100 000/µL | 20 | 16 | 20 |
| Hemorrhage characteristics . | Full-dose (n = 75) . | Modified-dose (n = 33) . | None (n = 13) . |
|---|---|---|---|
| Total hemorrhage, n (%) | 18 (24) | 5 (15) | 0 |
| Severity of hemorrhage, n (%) | |||
| Fatal hemorrhage | 1 (1) | 0 | 0 |
| Major hemorrhage | 8 (11) | 2 (6) | 0 |
| Clinically relevant nonmajor hemorrhage | 9 (12) | 2 (6) | 0 |
| Minor hemorrhage | 0 | 1 (3) | 0 |
| Type of hemorrhage | |||
| Intracranial hemorrhage | 2 (3) | 1 (3) | 0 |
| Ocular | 0 | 1 (3) | 0 |
| Upper gastrointestinal bleed | 1 (1) | 0 | 0 |
| Lower gastrointestinal bleed | 7 (9) | 1 (3) | 0 |
| Retroperitoneal | 1 (1) | 0 | 0 |
| Hematuria | 4 (5) | 0 | 0 |
| Mucocutaneous | 4 (5) | 2 (6) | 0 |
| Intramuscular | 1 (1) | 0 | 0 |
| Anticoagulant dose at time of hemorrhage | |||
| Full-dose | 15 (20) | 4 (12) | — |
| Modified-dose | 3 (4) | 1 (3) | — |
| None | 1 (1) | 0 | — |
| Anticoagulant at time of hemorrhage | |||
| LMWH | 10 (13) | 2 (6) | — |
| Unfractionated heparin | 4 (5) | 1 (3) | — |
| Direct oral anticoagulant | 4 (5) | 2 (6) | — |
| Median days with platelet count <100 000/µL | 20 | 16 | 20 |